Journal of neurology · 2008
Transcranial sonography in spinocerebellar ataxia type 2.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mijajlović Milija, Dragasević Natasa, Stefanova Elka, Petrović Igor, Svetel Marina, Kostić Vladimir S
Аннотация
OBJECTIVE: To study the use of transcranial brain parenchyma sonography (TCS), in particular the echogenic signal in the substantia nigra (SN), in patients with spinocerebellar ataxia type 2 (SCA2), recently recognized as an uncommon cause of parkinsonism.
METHODS: Six consecutive and unrelated SCA2 patients without parkinsonian signs, 30 consecutive patients with Parkinson's disease (PD), and 30 healthy, age- and sexmatched controls were prospectively studied with TCS according to a standardized protocol.
RESULTS: Four (67 %) of the six SCA2 patients exhibited SN hyperechogenicity. In two patients, the hyperechogenicity was classified as moderate (unilateral in both) and in two as marked. Differences between the SN echogenicity of the SCA2 group or the PD group and controls were statistically significant (p < 0.001), while there was no difference between the two groups of patients.
CONCLUSIONS: Transcranial brain parenchyma sonography detects SN hyperechogenicity in the majority of patients with SCA2 without parkinsonian signs. It would be important to reproduce our TCS findings in a larger number of SCA2 patients, as well as to test their possible significance in differentiating SCA2 from other types of SCA.
METHODS: Six consecutive and unrelated SCA2 patients without parkinsonian signs, 30 consecutive patients with Parkinson's disease (PD), and 30 healthy, age- and sexmatched controls were prospectively studied with TCS according to a standardized protocol.
RESULTS: Four (67 %) of the six SCA2 patients exhibited SN hyperechogenicity. In two patients, the hyperechogenicity was classified as moderate (unilateral in both) and in two as marked. Differences between the SN echogenicity of the SCA2 group or the PD group and controls were statistically significant (p < 0.001), while there was no difference between the two groups of patients.
CONCLUSIONS: Transcranial brain parenchyma sonography detects SN hyperechogenicity in the majority of patients with SCA2 without parkinsonian signs. It would be important to reproduce our TCS findings in a larger number of SCA2 patients, as well as to test their possible significance in differentiating SCA2 from other types of SCA.